Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 509.00
Bid: 506.00
Ask: 512.00
Change: 11.00 (2.20%)
Spread: 6.00 (1.186%)
Open: 503.00
High: 512.00
Low: 508.00
Prev. Close: 501.00
OCI Live PriceLast checked at -
Oakley Capital Investments is an Investment Trust

To achieve capital appreciation through investments in a diversified portfolio of private mid-market businesses primarily in Europe.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update for the Year Ended 31 December 2021

26 Jan 2022 07:00

RNS Number : 6216Z
Oakley Capital Investments Limited
26 January 2022
 

26 January 2022

Oakley Capital Investments Limited

Trading update for the year ended 31 December 2021

 

Strong earnings and realisations drive significant NAV uplift

 

Oakley Capital Investments Limited ("OCI" or the "Company") today announces a trading update for the 12 months ended 31 December 2021. OCI is a listed investment company providing consistent, long-term returns in excess of the FTSE All-Share Index by investing in the funds managed by Oakley Capital ("Oakley"), thereby capturing the outperformance of a leading private equity manager.

 

The Oakley Funds invest primarily in unquoted, pan-European businesses across three sectors: Technology, Consumer and Education. Oakley leverages its unique business founder network to source attractive investment opportunities and then applies proven value creation strategies to accelerate sustainable growth.

 

Highlights for the year ended 31 December 2021

Net Asset Value ("NAV") per share of 538 pence

Total NAV return per share of 35%

Total shareholder return of 48%

Investments of £137 million and share of proceeds of £121 million

Year-end cash of £163 million

Outstanding commitments of £404 million. Post year-end, OCI announces an initial €400 million (£336 million)1 commitment to Fund V

Buy-back and cancellation of 2 million shares

NAV growth

The Company's unaudited NAV as at 31 December 2021 was £961 million, which represents a NAV per share of 538 pence, based on portfolio company valuations at year-end. The total NAV per share return including dividends was 35% (+140 pence) since 31 December 2020 and 21% (+95 pence) since 30 June 2021. During the year, 76% of the increase in the portfolio's value was driven by EBITDA growth and 24% by multiple expansion including realisations. The largest contributions were from IU Group which continued to see strong growth in student enrolments during the period, and TechInsights whose sale has been agreed at a c.125%1 premium to the June book value.

Portfolio company performance

In 2021 the Oakley Funds continued to benefit from their investment focus on technology-enabled businesses. While some companies were impacted by COVID-related restrictions, the wider portfolio enjoyed strong earnings growth, benefiting from accelerating long-term trends such as the increasing adoption of digital solutions by businesses and consumers, and growing demand for quality, accessible education.

Proceeds

OCI's look-through share of proceeds from exits, refinancings and debt repayments during the period amounted to £121 million, consisting of: 

Realisations - £38 million - this includes the exit of ACE Education (2.1x Gross MM), the partial sale of Daisy Group's stake in the Digital Wholesale Solutions division and the repayment of debt by Daisy Group. Post period-end the exit of TechInsights is expected to generate a gross money multiple of c.18.7x, with OCI's share of proceeds c.£58 million1

Refinancings - £83 million - IU Group, Contabo and 7NXT all completed refinancings, demonstrating the quality of their recent earnings growth

Investments

During the period, OCI's Investment Adviser, Oakley Capital, continued to originate proprietary opportunities for its Funds across its focus sectors. OCI made a total look-through investment of £137 million attributable to:

 

New investments - £106 million - comprising idealista, Dexters and ICP Education in Fund IV; and ECOMMERCE ONE, Seedtag, and a reinvestment in ACE Education in the Origin Fund. Fund IV's reinvestment in TechInsights is expected to complete post period-end

Follow on investments - £31 million - comprising Windstar Medical in Fund IV; Grupo Primavera and Globe-Trotter in Fund III; and North Sails (Fund II and direct investment)

 

OCI also completed the buy-back and cancellation of two million shares at an average price of 354 pence per share during the period, resulting in a NAV uplift of c.1 pence.

 

Cash & Commitments

 

Balance sheet - OCI had cash on the balance sheet of £163 million at 31 December 2021, representing 17% of NAV, and no debt

New fund commitment - OCI announces an initial €400 million commitment (£336 million)1 to Fund V, the successor to Oakley Capital Fund IV, which is effectively c.75% invested

Total outstanding commitments - at the year-end outstanding Oakley Fund commitments were £404 million, which increases to £740 million when including the initial commitment to Fund V announced post year-end. This will be deployed in new Fund investments over the next five years, funded with existing balance sheet cash as well as expected proceeds from future realisations

The Company expects to report its audited annual results for 2021 on 10 March 2022.

 

- ends -

 

For further information please contact:

 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget, Investor Relations

 

Greenbrook Communications Limited

+44 20 7952 2000

Alex Jones / Michael Russell

 

Liberum Capital Limited (Financial Adviser & Broker)

+44 20 3100 2000

Chris Clarke / Darren Vickers / Owen Matthews

 

Notes:

This announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019.

LEI Number: 213800KW6MZUK12CQ815

1 Based on FX rates (USD:EUR 0.89; EUR:GBP 0.84) as at 25 January 2022.

 About Oakley Capital Investments Limited ("OCI")

OCI is a Specialist Fund Segment ("SFS") traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds.

A video introduction to OCI is available at https://oakleycapitalinvestments.com/videos/

The contents of the OCI website are not incorporated into, and do not form part of, this announcement.

Oakley Capital, the Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

The Oakley Funds

Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV and Oakley Capital Origin Fund are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.

Important information

Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.

The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

This announcement may include "forward-looking statements". These forward-looking statements are statements regarding the Company's objectives, intentions, beliefs or current expectations with respect to, amongst other things, the Company's financial position, business strategy, results of operations, liquidity, prospects and growth. Forward-looking statements are subject to risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Accordingly the Company's actual future financial results, operational performance and achievements may differ materially from those expressed in, or implied by, the statements. Given these uncertainties, prospective investors are cautioned not to place any undue reliance on such forward-looking statements, which speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the Company's expectations with regard to them or any change in events, conditions or circumstances on which any such statements are based unless required to do so by the Financial Services and Markets Act 2000, the Listing Rules or Prospectus Regulation Rules of the Financial Conduct Authority or other applicable laws, regulations or rules.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAPFSAANAEFA
Date   Source Headline
28th Jun 20247:00 amRNSOakley agrees sale of its investment in idealista
11th Jun 20247:00 amRNSOakley to invest in cybersecurity firm I-TRACING
7th Jun 20247:00 amRNSDirector Dealing
3rd Jun 20243:43 pmRNSResult of AGM
28th May 20247:00 amRNSOakley Capital invests in ProductLife Group
14th May 20247:00 amRNSOakley Capital invests in vitroconnect
8th May 20247:00 amRNSNotice of Annual General Meeting
24th Apr 20247:00 amRNSTrading Update for the 3 months ended 31 March 24
2nd Apr 20244:17 pmRNSUpdate from QuotedData
27th Mar 20247:00 amRNSDirector Dealing
27th Mar 20247:00 amRNSDirector Dealing
26th Mar 20245:46 pmRNSHolding(s) in Company
26th Mar 20245:32 pmRNSHolding(s) in Company
18th Mar 20247:00 amRNSOakley Capital invests in Horizons Optical
15th Mar 20244:00 pmRNSQuotedData's Weekly News & Interview
14th Mar 20245:32 pmRNSDividend Declaration
14th Mar 20247:00 amRNSAnnual Results 2023
4th Mar 20247:00 amRNSNotice of Results and Investor Presentation
15th Feb 20247:00 amRNSAppointment of Financial Adviser
13th Feb 20247:00 amRNSDirector Dealing
13th Feb 20247:00 amRNSDirector Dealing
24th Jan 20247:00 amRNSTrading Statement
16th Jan 20247:00 amRNSOakley agrees investment in Steer Automotive Group
15th Jan 20247:00 amRNSHolding(s) in Company
29th Dec 20237:00 amRNSSettlement of Fund I Loan
20th Dec 20239:39 amRNSUpdate from QuotedData
20th Dec 20237:00 amRNSHolding(s) in Company
28th Nov 20232:39 pmRNSResult of AGM
21st Nov 20237:00 amRNSDirector Dealing
7th Nov 20237:00 amRNSDirector Dealing
2nd Nov 20237:00 amRNSDirector Dealing
2nd Nov 20237:00 amRNSDirector Dealing
30th Oct 20237:00 amRNSNotice of AGM and Directorate Change
30th Oct 20237:00 amRNSInvestment in Alerce
26th Oct 202311:14 amRNSInvestment in Webcentral
25th Oct 20237:00 amRNSTrading update for the 3 months ended 30 Sep 2023
18th Oct 20237:00 amRNSHolding(s) in Company
18th Oct 20237:00 amRNSHolding(s) in Company
14th Sep 20235:53 pmRNSInterim Results 2023 - Replacement
14th Sep 20237:00 amRNSInterim Results for the 6 months ended 30 June 23
30th Aug 20237:00 amRNSNotice of Results and Investor Presentation
10th Aug 20237:00 amRNSOakley invests in three dental labs businesses
31st Jul 202312:14 pmRNSDirector Dealing
28th Jul 20232:27 pmRNSDirector Dealing
26th Jul 20237:00 amRNSTrading update for the 6 months ended 30 June 2023
26th Jun 20237:00 amRNSDirector Dealing
26th Jun 20237:00 amRNSDirector Dealing
19th Jun 202311:44 amRNSDirector Dealing
22nd May 202310:51 amRNSDirector Dealing
22nd May 202310:51 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.